BR9712589A - Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica. - Google Patents

Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.

Info

Publication number
BR9712589A
BR9712589A BR9712589-0A BR9712589A BR9712589A BR 9712589 A BR9712589 A BR 9712589A BR 9712589 A BR9712589 A BR 9712589A BR 9712589 A BR9712589 A BR 9712589A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treat
prostate cancer
conjugate
processes
Prior art date
Application number
BR9712589-0A
Other languages
English (en)
Inventor
Victor GARSKY
Dong-Mei Feng
Deborah Defeo-Jones
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9712589A publication Critical patent/BR9712589A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"CONJUGADO, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA TRATAR C‰NCER DE PRóSTATA, PARA TRATAR HIPERPLASIA PROSTáTICA BENIGNA, E, PARA FAZER UMA COMPOSIçãO FARMACêUTICA". Conjugados químicos que compreendem oligopeptídeos, tendo sequências de aminoácidos que são seletivamente proteoliticamente clivadas por antígeno específico de próstata livre (PSA) e agentes citotóxicos conhecidos são descritos. Estes conjugados são utilizáveis no tratamento de câncer prostático e hipertropia prostática benigna (BPH).
BR9712589-0A 1996-10-30 1997-10-27 Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica. BR9712589A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer
PCT/US1997/019225 WO1998018493A2 (en) 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
BR9712589A true BR9712589A (pt) 1999-10-26

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712589-0A BR9712589A (pt) 1996-10-30 1997-10-27 Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.

Country Status (32)

Country Link
EP (1) EP0942754B1 (pt)
JP (1) JP2000509407A (pt)
KR (1) KR100508199B1 (pt)
AR (1) AR008907A1 (pt)
AT (1) ATE239509T1 (pt)
AU (1) AU726434B2 (pt)
BG (1) BG64768B1 (pt)
BR (1) BR9712589A (pt)
CA (1) CA2268738A1 (pt)
CO (1) CO4930281A1 (pt)
CZ (1) CZ155599A3 (pt)
DE (1) DE69721810T2 (pt)
DK (1) DK0942754T3 (pt)
DZ (1) DZ2333A1 (pt)
EA (1) EA002066B1 (pt)
EE (1) EE03858B1 (pt)
ES (1) ES2196374T3 (pt)
HK (1) HK1024876A1 (pt)
HR (1) HRP970566A2 (pt)
HU (1) HUP0000651A3 (pt)
ID (1) ID21358A (pt)
IL (1) IL129356A0 (pt)
IS (1) IS5025A (pt)
NO (1) NO992069L (pt)
PE (1) PE17399A1 (pt)
PL (1) PL333004A1 (pt)
PT (1) PT942754E (pt)
SK (1) SK57399A3 (pt)
TR (1) TR199901485T2 (pt)
TW (1) TW425286B (pt)
WO (1) WO1998018493A2 (pt)
YU (1) YU21399A (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002745B1 (ru) * 1997-12-02 2002-08-29 Мерк Энд Ко., Инк. Конъюгаты, которые можно использовать при лечении рака предстательной железы
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
AU764603B2 (en) * 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DK1144011T3 (da) * 1998-12-11 2010-07-05 Coulter Pharm Inc Pro-drug-forbindelser og fremgangsmåde til fremstilling deraf
WO2001028593A2 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
CA2387901A1 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
MXPA02009019A (es) * 2000-03-15 2003-02-12 Du Pont Pharm Co Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico.
EP1490090A4 (en) * 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
WO2008067495A2 (en) * 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
KR101472316B1 (ko) * 2009-03-09 2014-12-12 케이티비 투머포슝스케쉘샤프트 엠비에이치 프로드러그
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
MX358660B (es) 2012-01-12 2018-08-30 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
ES2873846T3 (es) 2015-11-19 2021-11-04 Revitope Ltd Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
WO1998018493A3 (en) 1998-07-23
CZ155599A3 (cs) 1999-10-13
AU726434B2 (en) 2000-11-09
HUP0000651A2 (hu) 2000-06-28
PE17399A1 (es) 1999-02-20
HRP970566A2 (en) 1998-08-31
AR008907A1 (es) 2000-02-23
NO992069D0 (no) 1999-04-29
BG64768B1 (bg) 2006-03-31
SK57399A3 (en) 2000-01-18
CO4930281A1 (es) 2000-06-27
EA002066B1 (ru) 2001-12-24
DE69721810T2 (de) 2004-03-11
KR100508199B1 (ko) 2005-08-17
BG103436A (en) 2000-04-28
EP0942754A2 (en) 1999-09-22
ID21358A (id) 1999-05-27
HUP0000651A3 (en) 2001-12-28
WO1998018493A2 (en) 1998-05-07
EP0942754B1 (en) 2003-05-07
HK1024876A1 (en) 2000-10-27
ATE239509T1 (de) 2003-05-15
DE69721810D1 (de) 2003-06-12
TW425286B (en) 2001-03-11
KR20000052970A (ko) 2000-08-25
JP2000509407A (ja) 2000-07-25
YU21399A (sh) 2000-03-21
PT942754E (pt) 2003-08-29
IL129356A0 (en) 2000-02-17
AU5149798A (en) 1998-05-22
IS5025A (is) 1999-04-13
NO992069L (no) 1999-06-30
DZ2333A1 (fr) 2002-12-28
ES2196374T3 (es) 2003-12-16
EE9900179A (et) 1999-12-15
EA199900428A1 (ru) 2000-02-28
TR199901485T2 (xx) 1999-08-23
DK0942754T3 (da) 2003-08-04
PL333004A1 (en) 1999-11-08
CA2268738A1 (en) 1998-05-07
EE03858B1 (et) 2002-10-15

Similar Documents

Publication Publication Date Title
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
BR0115953A (pt) Complexos de derivados de fosfato
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
PT771209E (pt) Novos peptideos
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
EP2311490A3 (en) Uses of antibodies to aminophospholipids for cancer treatment
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
BR9815116A (pt) Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna
EP1009420A4 (en) CONJUGATES WHICH ARE USEFUL IN TREATING PROSTATE CANCER
PT1003496E (pt) Medicamento para tratamento de neoplasia intra-epitelial prostatica
DE69603827T2 (de) Waisen-rezeptor
WO2004041828A1 (en) Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
TR200000903T2 (tr) Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar.
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
YU34400A (sh) Konjugati korisni u lečenju kancera prostate
ECSP972297A (es) Conjugados utiles en el tratamiento de cancer de prostata
ECSP982763A (es) Conjugados utiles en el tratamiento de cancer de prostata
WO1999044628A8 (en) Conjugates useful in the treatment of prostate cancer
DE69807166D1 (de) Prostata-spezifische Antigen Inhibitore
TH55852A (th) คอนจูเกทมีประโยชน์ในการรักษามะเร็งต่อมลูกหมาก

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/47 (2006.01), A61K 47/62 (2017.0